features: Chronic Lymphocytic Leukemia
Non-covalent BTK inhibitor LOXO-305 shows promising results in advanced B-cell malignancies
Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…
The CLL Sessions: post-ASH 2020 roundtable discussion
A session with experts John Gribben, Alessandra Tedeschi, Meghan Thompson & Matthew Davids, who discuss the latest chronic lymphocytic leukemia…
The VJ Sessions:
Roundtable discussions with leading experts in hemonc
VJHemOnc brings you roundtable discussions with leading hematological experts in myeloma, AML, CLL, ALL, lymphoma, MDS and MPNs.
SOHO Italy 2020 Virtual Meeting
VJHemOnc is proud to present the SOHO Italy 2020 Virtual Meeting, which took place on the 22nd-24th of September 2020.
ERIC 2020 Presentations
VJHemOnc was official Media Partner for the ERIC 2020 Virtual Meeting, New Frontiers in CLL Research, which took place on 1-3…
FDA clears first in vitro diagnostic MRD assay for CLL
The U.S. Food and Drug Administration (FDA) has approved the first and only assay – clonoSEQ®, to screen and assess…
The CLL Sessions: ASCO & EHA 2020 updates
A five-part session with experts John Gribben, Barbara Eichhorst, Susan O’Brien and Matthew Davids who debate the key updates in…
EHA 2020 Top Picks
VJHemOnc are excited to present late-breaking abstracts and key trial updates announced at this year’s virtual EHA meeting!
FDA approve ibrutinib and rituximab combination for CLL
Following positive results gleaned from the E1912 trial (NCT02048813), the U.S. Food and Drug Administration (FDA) has expanded the indication…
The impact of genetic mutations on the performance of anti-CD19 CAR T-cells in CLL
Chimeric antigen receptor T-cell (CAR-T) therapies have proven particularly successful in hematological malignancies. However, CAR T-cells still underperform when used…
Discover the next-generation of MRD assessment
Discover the next-generation of MRD assessment. Gain insights into the science of molecular testing and its potential